Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 2
2020 3
2021 1
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, Banek S, Guadalupi V, Ku JH, Valderrama BP, Tran B, Triantos S, Kean Y, Akapame S, Deprince K, Mukhopadhyay S, Stone NL, Siefker-Radtke AO; THOR Cohort 1 Investigators. Loriot Y, et al. N Engl J Med. 2023 Nov 23;389(21):1961-1971. doi: 10.1056/NEJMoa2308849. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870920 Clinical Trial.
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y; THOR cohort 2 investigators. Siefker-Radtke AO, et al. Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871702 Clinical Trial.
Republished: Immune checkpoint inhibitor induced large vessel vasculitis.
Henderson D, Eslamian G, Poon D, Crabb S, Jones R, Sankey P, Kularatne B, Linch M, Josephs D. Henderson D, et al. Among authors: sankey p. Drug Ther Bull. 2021 Feb;59(2):29-31. doi: 10.1136/dtb.2020.233496rep. Epub 2020 Oct 22. Drug Ther Bull. 2021. PMID: 33093074 No abstract available.
A practical guide to medical ethics for intensivists.
Innes R, Montgomery H, Bolton J, Rowland M, Hannam A, Lindsay S, Sankey P. Innes R, et al. Among authors: sankey p. J Intensive Care Soc. 2019 Feb;20(1):66-73. doi: 10.1177/1751143718759456. Epub 2018 Mar 13. J Intensive Care Soc. 2019. PMID: 30792765 Free PMC article.
Immune checkpoint inhibitor induced large vessel vasculitis.
Henderson D, Eslamian G, Poon D, Crabb S, Jones R, Sankey P, Kularatne B, Linch M, Josephs D. Henderson D, et al. Among authors: sankey p. BMJ Case Rep. 2020 May 18;13(5):e233496. doi: 10.1136/bcr-2019-233496. BMJ Case Rep. 2020. PMID: 32430351 Free PMC article. Corrected and republished.
A practical guide to medical ethics for intensivists: Part 2.
Innes R, Montgomery H, Bolton J, Rowland M, Hannam A, Sankey P, Lindsay S. Innes R, et al. Among authors: sankey p. J Intensive Care Soc. 2019 May;20(2):98-105. doi: 10.1177/1751143718759457. Epub 2018 Mar 13. J Intensive Care Soc. 2019. PMID: 31037101 Free PMC article. No abstract available.
PEARLS - A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA-avid pelvic and/or para-aortic lymph nodes at presentation.
Murray J, Cruickshank C, Bird T, Bell P, Braun J, Chuter D, Ferreira MR, Griffin C, Hassan S, Hujairi N, Melcher A, Miles E, Naismith O, Panades M, Philipps L, Reid A, Rekowski J, Sankey P, Staffurth J, Syndikus I, Tree A, Wilkins A, Hall E; PEARLS Trial Management Group. Murray J, et al. Among authors: sankey p. Clin Transl Radiat Oncol. 2022 Sep 24;37:130-136. doi: 10.1016/j.ctro.2022.09.003. eCollection 2022 Nov. Clin Transl Radiat Oncol. 2022. PMID: 36238579 Free PMC article.